Showing results (61-70 of 85) with videos related to
Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemiaJohn Moore, Ian Nivison-Smith, Kim Goh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significancePeter Jantscheff, Luigi Terracciano, Adam Lowy, et al.International Journal of Cancer|October 25, 2002
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancerGabriele Mild, Felix Bachmann, Jean-Louis Boulay, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer ResearchDieter Koeberle, Piercarlo Saletti, Markus Borner, et al.The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.Leukemia & Lymphoma|November 17, 2006
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphomaMax Wolf, Mark Bentley, Paula Marlton, et al.Cancer Gene Therapy|March 16, 2002
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levelsChristoph Rochlitz, Brigitte Dreno, Peter Jantscheff, et al.Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.Breast Cancer Research and Treatment|September 21, 2004
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?Marzio E E Sabbioni, Jürg Bernhard, Hans-Peter Siegrist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter studyMiklos Pless, Karim Belhadj, Hans D Menssen, et al.Pageof 9